Teva increases its global position with acquisition of Ratiopharm

INICIO/Noticias Farmacéuticas | Posted 10/09/2010 post-comment0 Post your comment

Generics are becoming an increasingly lucrative market with good prospects for the future. However, a report by US market data provider BCC Research shows that this is also a bit of an exclusive club. The top four global generics manufacturers in 2009 – Teva, Sandoz, Mylan and Watson – accounted for 40% of the world market.

picture35

Teva, with an 18% market share in 2009, is reinforcing its global number one position with the recent acquisition of the 5th largest generic manufacturer, Ratiopharm. This move has increased both its global position and has propelled it to the number one position in Europe.

Teva's President and CEO, Mr Shlomo Yanai, commented that “increasing Teva's market share in Europe – a geography with tremendous potential for generics penetration – is an important pillar of our long-term growth strategy. With the acquisition of Ratiopharm we will become the leader in key European markets and we are well-positioned to become the leader in many other European markets in the near future".

Related article

Teva with ratiopharm market leader in European generics

References

BCC Research. Generic Drugs: The Global Market. Report Code: PHM009E, Published: July 2009

Teva Press Release. Teva Completes Acquisition of ratiopharm. 10 August 2010

comment icon Comments (0)
Post your comment
Related content
Spinoff updates: Merck’s Organon and Novartis’ Sandoz
24 AA011041
INICIO/Noticias Farmacéuticas Posted 26/11/2021
Swiss Social Democrat’s for nationalization of Sandoz
28 MD002360
INICIO/Noticias Farmacéuticas Posted 19/11/2021
Ustekinumab biosimilars: new international biopharma agreements
Contract Tender V13H30
INICIO/Noticias Farmacéuticas Posted 12/11/2021
Biocon Biologics and Serum Institute Life Sciences partnership
64 MD002129
INICIO/Noticias Farmacéuticas Posted 12/11/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010